Kenneth Yan1, Kailin Yang, Jeremy N Rich. 1. aDepartment of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic bCase Western Reserve University School of Medicine cDepartment of Cell Biology, Case Western Reserve University dCleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Abstract
PURPOSE OF REVIEW: Recent advances in the role of cancer stem cells (CSCs) in glioblastoma will be reviewed. RECENT FINDINGS: In the decade since the description of brain tumor CSCs, the potential significance of these cells in tumor growth, therapeutic resistance, and spread has become evident. Most recently, the interplay between CSCs, tumor genetics, and the microenvironment has offered potential nodes of fragility under therapeutic development. The CSC phenotype is informed by specific receptor signaling, and study of the regulation of stem cell genes by transcription factors and microRNAs has identified a number of new targets amenable to treatment. Like normal stem cells, CSCs display specific epigenetic landscapes and metabolic profiles. SUMMARY: Brain cancers activate core stem cell regulatory pathways to empower self-renewal, maintenance of an organ system (albeit an aberrant one), and survival under stress that collectively permits tumor growth, therapeutic resistance, invasion, and angiogenesis. These properties have implicated CSCs as contributors in GBM progression and recurrence, spurring a search for anti-CSC therapies that do not disrupt normal stem cell maintenance. The last year has witnessed a rapid evolution in the understanding of CSC biology to inform preclinical targeting.
PURPOSE OF REVIEW: Recent advances in the role of cancer stem cells (CSCs) in glioblastoma will be reviewed. RECENT FINDINGS: In the decade since the description of brain tumor CSCs, the potential significance of these cells in tumor growth, therapeutic resistance, and spread has become evident. Most recently, the interplay between CSCs, tumor genetics, and the microenvironment has offered potential nodes of fragility under therapeutic development. The CSC phenotype is informed by specific receptor signaling, and study of the regulation of stem cell genes by transcription factors and microRNAs has identified a number of new targets amenable to treatment. Like normal stem cells, CSCs display specific epigenetic landscapes and metabolic profiles. SUMMARY:Brain cancers activate core stem cell regulatory pathways to empower self-renewal, maintenance of an organ system (albeit an aberrant one), and survival under stress that collectively permits tumor growth, therapeutic resistance, invasion, and angiogenesis. These properties have implicated CSCs as contributors in GBM progression and recurrence, spurring a search for anti-CSC therapies that do not disrupt normal stem cell maintenance. The last year has witnessed a rapid evolution in the understanding of CSC biology to inform preclinical targeting.
Authors: Christine E Eyler; Wen-Chi Foo; Katherine M LaFiura; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich Journal: Stem Cells Date: 2008-09-18 Impact factor: 6.277
Authors: Ping Mao; Kaushal Joshi; Jianfeng Li; Sung-Hak Kim; Peipei Li; Lucas Santana-Santos; Soumya Luthra; Uma R Chandran; Panayiotis V Benos; Luke Smith; Maode Wang; Bo Hu; Shi-Yuan Cheng; Robert W Sobol; Ichiro Nakano Journal: Proc Natl Acad Sci U S A Date: 2013-05-06 Impact factor: 11.205
Authors: Peter W Lewis; Manuel M Müller; Matthew S Koletsky; Francisco Cordero; Shu Lin; Laura A Banaszynski; Benjamin A Garcia; Tom W Muir; Oren J Becher; C David Allis Journal: Science Date: 2013-03-28 Impact factor: 47.728
Authors: Jakub Godlewski; Michal O Nowicki; Agnieszka Bronisz; Shanté Williams; Akihiro Otsuki; Gerard Nuovo; Abhik Raychaudhury; Herbert B Newton; E Antonio Chiocca; Sean Lawler Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701
Authors: D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler Journal: Science Date: 2008-09-04 Impact factor: 47.728
Authors: Esther Rheinbay; Mario L Suvà; Shawn M Gillespie; Hiroaki Wakimoto; Anoop P Patel; Mohammad Shahid; Ozgur Oksuz; Samuel D Rabkin; Robert L Martuza; Miguel N Rivera; David N Louis; Simon Kasif; Andrew S Chi; Bradley E Bernstein Journal: Cell Rep Date: 2013-05-23 Impact factor: 9.423
Authors: Dou Yu; Omar F Khan; Mario L Suvà; Biqin Dong; Wojciech K Panek; Ting Xiao; Meijing Wu; Yu Han; Atique U Ahmed; Irina V Balyasnikova; Hao F Zhang; Cheng Sun; Robert Langer; Daniel G Anderson; Maciej S Lesniak Journal: Proc Natl Acad Sci U S A Date: 2017-07-10 Impact factor: 11.205
Authors: Javier Megías; Alba Martínez; Teresa San-Miguel; Rosario Gil-Benso; Lisandra Muñoz-Hidalgo; David Albert-Bellver; Amara Carratalá; Daniel Gozalbo; Concha López-Ginés; María Luisa Gil; Miguel Cerdá-Nicolás Journal: Invest New Drugs Date: 2019-05-11 Impact factor: 3.850
Authors: L Treps; S Edmond; E Harford-Wright; E M Galan-Moya; A Schmitt; S Azzi; A Citerne; N Bidère; D Ricard; J Gavard Journal: Oncogene Date: 2015-09-14 Impact factor: 9.867
Authors: C J O'Regan; H Kearney; A Beausang; M A Farrell; F M Brett; J B Cryan; T E Loftus; P G Buckley Journal: J Neurooncol Date: 2017-12-20 Impact factor: 4.130